Solid moves up timeline for IGNITE DMD readout

Solid Biosciences Inc. (NASDAQ:SLDB) expects preliminary data from the Phase I/II IGNITE DMD trial of microdystrophin gene transfer therapy SGT-001 to treat Duchenne muscular dystrophy (DMD) in 1Q19, up from 1H19 that was guided previously. The company provided the update in its 3Q18 financial report.

In June, FDA lifted a clinical hold on IGNITE DMD that agency had placed in March after the first patient treated with SGT-001 was hospitalized (see "FDA Lifts Clinical Hold on Solid's DMD Gene Therapy")...